Answers are grounded in this paper and cite their sources.
Bioorthogonal prodrug activation offers a promising approach for site-specific drug release, significantly reducing the systemic toxicity associated with conventional chemotherapy. However, challenges remain in precisely controlling prodrug activation at the target site while maintaining optimal selectivity, reactivity, and potency. Here, we report a dual-targeting peptide, TzFFY p HH, that integrates on-membrane enzyme-instructed self-assembly (EISA) with bioorthogonal chemistry to enable selective chemotherapy. Exploiting the overexpression of alkaline phosphatase (ALP) and programmed death-ligand 1 (PD-L1) on cancer cells, TzFFY p HH selectively anchors and self-assembles on the cancer cell membrane, enriching tetrazine (Tz) handles that act as bioorthogonal reactors to activate a trans -cyclooctene (TCO)-caged prodrug (TCO-Dox) for precise drug release. Upon topical administration, TzFFY p HH forms a hydrogel at subcutaneous tumor sites, enabling in situ prodrug activation for effective tumor inhibition. Notably, this localized chemotherapy elicits a potent antitumor immune response, which, when combined with anti-programmed death-1 antibody (αPD-1), synergistically potentiates therapeutic outcomes. By coupling supramolecular self-assembly with bioorthogonal reactivity on the cell membrane, this work establishes a chemically programmable platform for spatiotemporally controlled prodrug activation and provides a general strategy for integrating localized chemotherapy with immunotherapy.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: